2025-02-132026-02-282026-02-28false16250344CLINICAL VASCULAR SCIENCE UK LIMITED2026-09-1472110falseiso4217:GBPxbrli:pure162503442025-02-12162503442026-02-28162503442025-02-132026-02-28162503442025-02-11162503442025-02-12162503442025-02-122025-02-1216250344bus:SmallEntities2025-02-132026-02-2816250344bus:AuditExempt-NoAccountantsReport2025-02-132026-02-2816250344bus:FullAccounts2025-02-132026-02-2816250344bus:PrivateLimitedCompanyLtd2025-02-132026-02-2816250344core:WithinOneYear2026-02-2816250344core:AfterOneYear2026-02-2816250344core:WithinOneYear2025-02-1216250344core:AfterOneYear2025-02-1216250344core:ShareCapital2026-02-2816250344core:SharePremium2026-02-2816250344core:RevaluationReserve2026-02-2816250344core:OtherReservesSubtotal2026-02-2816250344core:RetainedEarningsAccumulatedLosses2026-02-2816250344core:ShareCapital2025-02-1216250344core:SharePremium2025-02-1216250344core:RevaluationReserve2025-02-1216250344core:OtherReservesSubtotal2025-02-1216250344core:RetainedEarningsAccumulatedLosses2025-02-1216250344core:LandBuildings2026-02-2816250344core:PlantMachinery2026-02-2816250344core:Vehicles2026-02-2816250344core:FurnitureFittings2026-02-2816250344core:OfficeEquipment2026-02-2816250344core:NetGoodwill2026-02-2816250344core:IntangibleAssetsOtherThanGoodwill2026-02-2816250344core:ListedExchangeTraded2026-02-2816250344core:UnlistedNon-exchangeTraded2026-02-2816250344core:LandBuildings2025-02-1216250344core:PlantMachinery2025-02-1216250344core:Vehicles2025-02-1216250344core:FurnitureFittings2025-02-1216250344core:OfficeEquipment2025-02-1216250344core:NetGoodwill2025-02-1216250344core:IntangibleAssetsOtherThanGoodwill2025-02-1216250344core:ListedExchangeTraded2025-02-1216250344core:UnlistedNon-exchangeTraded2025-02-1216250344core:LandBuildings2025-02-132026-02-2816250344core:PlantMachinery2025-02-132026-02-2816250344core:Vehicles2025-02-132026-02-2816250344core:FurnitureFittings2025-02-132026-02-2816250344core:OfficeEquipment2025-02-132026-02-2816250344core:NetGoodwill2025-02-132026-02-2816250344core:IntangibleAssetsOtherThanGoodwill2025-02-132026-02-2816250344core:ListedExchangeTraded2025-02-132026-02-2816250344core:UnlistedNon-exchangeTraded2025-02-132026-02-2816250344core:MoreThanFiveYears2025-02-132026-02-2816250344core:Non-currentFinancialInstruments2026-02-2816250344core:Non-currentFinancialInstruments2025-02-1216250344dpl:CostSales2025-02-132026-02-2816250344dpl:DistributionCosts2025-02-132026-02-2816250344core:LandBuildings2025-02-132026-02-2816250344core:PlantMachinery2025-02-132026-02-2816250344core:Vehicles2025-02-132026-02-2816250344core:FurnitureFittings2025-02-132026-02-2816250344core:OfficeEquipment2025-02-132026-02-2816250344dpl:AdministrativeExpenses2025-02-132026-02-2816250344core:NetGoodwill2025-02-132026-02-2816250344core:IntangibleAssetsOtherThanGoodwill2025-02-132026-02-2816250344dpl:GroupUndertakings2025-02-132026-02-2816250344dpl:ParticipatingInterests2025-02-132026-02-2816250344dpl:GroupUndertakingscore:ListedExchangeTraded2025-02-132026-02-2816250344core:ListedExchangeTraded2025-02-132026-02-2816250344dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-02-132026-02-2816250344core:UnlistedNon-exchangeTraded2025-02-132026-02-2816250344dpl:CostSales2025-02-122025-02-1216250344dpl:DistributionCosts2025-02-122025-02-1216250344core:LandBuildings2025-02-122025-02-1216250344core:PlantMachinery2025-02-122025-02-1216250344core:Vehicles2025-02-122025-02-1216250344core:FurnitureFittings2025-02-122025-02-1216250344core:OfficeEquipment2025-02-122025-02-1216250344dpl:AdministrativeExpenses2025-02-122025-02-1216250344core:NetGoodwill2025-02-122025-02-1216250344core:IntangibleAssetsOtherThanGoodwill2025-02-122025-02-1216250344dpl:GroupUndertakings2025-02-122025-02-1216250344dpl:ParticipatingInterests2025-02-122025-02-1216250344dpl:GroupUndertakingscore:ListedExchangeTraded2025-02-122025-02-1216250344core:ListedExchangeTraded2025-02-122025-02-1216250344dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-02-122025-02-1216250344core:UnlistedNon-exchangeTraded2025-02-122025-02-1216250344core:NetGoodwill2026-02-2816250344core:IntangibleAssetsOtherThanGoodwill2026-02-2816250344core:LandBuildings2026-02-2816250344core:PlantMachinery2026-02-2816250344core:Vehicles2026-02-2816250344core:FurnitureFittings2026-02-2816250344core:OfficeEquipment2026-02-2816250344core:AfterOneYear2026-02-2816250344core:WithinOneYear2026-02-2816250344core:ListedExchangeTraded2026-02-2816250344core:UnlistedNon-exchangeTraded2026-02-2816250344core:ShareCapital2026-02-2816250344core:SharePremium2026-02-2816250344core:RevaluationReserve2026-02-2816250344core:OtherReservesSubtotal2026-02-2816250344core:RetainedEarningsAccumulatedLosses2026-02-2816250344core:NetGoodwill2025-02-1216250344core:IntangibleAssetsOtherThanGoodwill2025-02-1216250344core:LandBuildings2025-02-1216250344core:PlantMachinery2025-02-1216250344core:Vehicles2025-02-1216250344core:FurnitureFittings2025-02-1216250344core:OfficeEquipment2025-02-1216250344core:AfterOneYear2025-02-1216250344core:WithinOneYear2025-02-1216250344core:ListedExchangeTraded2025-02-1216250344core:UnlistedNon-exchangeTraded2025-02-1216250344core:ShareCapital2025-02-1216250344core:SharePremium2025-02-1216250344core:RevaluationReserve2025-02-1216250344core:OtherReservesSubtotal2025-02-1216250344core:RetainedEarningsAccumulatedLosses2025-02-1216250344core:NetGoodwill2025-02-1116250344core:IntangibleAssetsOtherThanGoodwill2025-02-1116250344core:LandBuildings2025-02-1116250344core:PlantMachinery2025-02-1116250344core:Vehicles2025-02-1116250344core:FurnitureFittings2025-02-1116250344core:OfficeEquipment2025-02-1116250344core:AfterOneYear2025-02-1116250344core:WithinOneYear2025-02-1116250344core:ListedExchangeTraded2025-02-1116250344core:UnlistedNon-exchangeTraded2025-02-1116250344core:ShareCapital2025-02-1116250344core:SharePremium2025-02-1116250344core:RevaluationReserve2025-02-1116250344core:OtherReservesSubtotal2025-02-1116250344core:RetainedEarningsAccumulatedLosses2025-02-1116250344core:AfterOneYear2025-02-132026-02-2816250344core:WithinOneYear2025-02-132026-02-2816250344core:Non-currentFinancialInstrumentscore:CostValuation2025-02-132026-02-2816250344core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-02-132026-02-2816250344core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-02-132026-02-2816250344core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-02-132026-02-2816250344core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-02-132026-02-2816250344core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-02-132026-02-2816250344core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-02-132026-02-2816250344core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-02-132026-02-2816250344core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-02-132026-02-2816250344core:Non-currentFinancialInstrumentscore:CostValuation2026-02-2816250344core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-02-2816250344core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-02-2816250344core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-02-2816250344core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-02-2816250344core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-02-2816250344core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2026-02-2816250344core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-02-2816250344core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-02-2816250344core:Non-currentFinancialInstrumentscore:CostValuation2025-02-1216250344core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-02-1216250344core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-02-1216250344core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-02-1216250344core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-02-1216250344core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-02-1216250344core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-02-1216250344core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-02-1216250344core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-02-1216250344bus:Director12025-02-132026-02-28

CLINICAL VASCULAR SCIENCE UK LIMITED

Registered Number
16250344
(England and Wales)

Unaudited Financial Statements for the Period ended
28 February 2026

CLINICAL VASCULAR SCIENCE UK LIMITED
Company Information
for the period from 13 February 2025 to 28 February 2026

Director

Dr Steven Rogers

Registered Address

179 Park Lane
Poynton
SK12 1RH

Registered Number

16250344 (England and Wales)
CLINICAL VASCULAR SCIENCE UK LIMITED
Balance Sheet as at
28 February 2026

Notes

2026

£

£

Current assets
Debtors31,740
Cash at bank and on hand2,975
4,715
Creditors amounts falling due within one year4(3,542)
Net current assets (liabilities)1,173
Total assets less current liabilities1,173
Net assets1,173
Capital and reserves
Called up share capital100
Profit and loss account1,073
Shareholders' funds1,173
The financial statements were approved and authorised for issue by the Director on 14 September 2026, and are signed on its behalf by:
Dr Steven Rogers
Director
Registered Company No. 16250344
CLINICAL VASCULAR SCIENCE UK LIMITED
Notes to the Financial Statements
for the period ended 28 February 2026

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Current taxation
Income tax expense represents the sum of the tax currently payable and deferred tax. The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the profit and loss account because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
2.Average number of employees

2026
Average number of employees during the year0
3.Debtors: amounts due within one year

2026

£
Trade debtors / trade receivables1,740
Total1,740
Short term trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method, less impairment losses for bad and doubtful debts.
4.Creditors: amounts due within one year

2026

£
Taxation and social security252
Other creditors3,290
Total3,542
Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
5.Provisions for liabilities
Provisions are made where an event has taken place that gives the company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of going the amount of the obligation. Provisions are charged as an expense to the profit and loss account in the year that the company becomes aware of the obligation and are measured at the best estimate at balance sheet date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties. When payments are eventually made, they are charged to the provision carried in the balance sheet.